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Thromboxane (TX) A2 is an important bronchoconstrictor in the pathogenesis of asthma. Seratrodast, known as 
AA-2414, is a new oral TXA2 receptor antagonist which is currently prescribed in asthma therapy in Japan. 
However its clinical effects have been very different in individual subjects. 
To assess whether the clinical efficacy of TXAZ antagonist is predictable on the basis of urinary arachidonic acid 
metabolites in urine of patients with asthma, an open and multicentre trial was conducted. Fifty adult asthmatic 
subjects (women/men = 28/22) were enrolled [resting mean forced expiratory volume in 1 set (FEVi)% was 82%; 
range, 5&96%]. Urinary levels of 1 I-dehydro-TXBz, leukotriene (LT) Ed, 2,3-dinor-6-keto-prostaglandin Frcl and 
creatinine in 3-h urine collected in the morning at the start of seratrodast (80 mgday-‘, once a day at evening for 4 
weeks) were measured. Responders were defined by improvements of asthma symptoms score and peak expiratory 
flow rate (PEFR). 
Of the 50 subjects, 45 completed this study. Eighteen patients were responders and the other 27 were non- 
responders. There were no significant differences between the two groups in patients’ characteristics, baseline lung 
functions, treatments and baseline urinary eisosanoids. The 1 1-dehydro-TXBz/LTEd ratio of responders was 
significantly higher (P = 0.0091) than that of non-responders (mean + SE, 7.49 f 0.71 KS. 5.09 -t 0.67). Eleven patients 
out of 18 responders agreed to continue this drug for 6 months, the 11 -dehydro- TXB2/LTE4 ratio decreased during 
this period, but not significantly. 
Our data demonstrated that responders and non-responders to TXA2 receptor antagonist existed in patients with 
asthma, and it suggests that the ratio of urinary eicosanoids might be a possible predictor of the effects of TXAz 
receptor antagonist. 
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Introduction 
Thromboxane (TX) AZ, leukotrienes (LTs) and prostaglan- 
dins (PGs) are synthesized from arachidonic acids that are 
released from the cell-membrane phospholipid bilayer by 
phosphlipase AZ. 
In arachidonates, TXA2, LTs, PGF2, and PGD2 appear 
to be potent bronchoconstrictors and PGEs and PGIl are 
capable of protecting against airway narrowing (1). Urinary 
1 1-dehydro-TXBs, LTE4 and 2,3-dinor-6-keto PGFi, may 
be reliable indicators of TXA2, LTs and PGIs, respectively 
(2,3). Urinary 11-dehydro-TXBz and LTE4 levels are 
significantly increased in response to allergen challenge 
Received 4 March 1999 and accepted in revised form 8 July 1999. 
Correspondence should be addressed to H. Tanaka, Third 
Department of Internal Medicine, Sapporo Medical University 
School of Medicine, South-l, West-16, Chuo-ku, Sapporo 060- 
8543, Japan. Fax: +81-11-613-1543. 
0954-6111/99/120891+07 $12+00/O 
0 1999 HARCOURT PUBLISHERS LTD 
and spontaneous exacerbation in asthmatic subjects (4-6). 
TXAz is known to be a potent constrictor of the airway and 
vascular smooth muscle, to cause platelet aggregation and 
to lead to airway hyper-responsiveness (7-9). U-46619, a 
stable TXAl mimetic, has been reported to cause airway 
hyper-responsiveness in humans (10). Recently, Wenzel et 
al. (11) reported the ongoing release of 1 1-dehydro-TXBz 
into bronchoalveolar lavage fluid in severe asthmatic 
patients, treated with high doses of oral glucocorticoids. 
On the other hand, in the guinea pig airway, LTD4 induced 
bronchoconstriction directly and indirectly by the release of 
TXA2 (12). Circulating TXAl and PGI2 were increased 
after infusion with LTC4 (13). These eicosanoids may 
influence each other in their production pathways. 
Seratrodast [AA-2414; (+)-7-(3, 5, 6-trimethyl-1,4-ben- 
zoquinone-2-yl)-7-phenylheptanoic acid] is a potent com- 
petitive TXA2 receptor antagonist in vivo and in vitro (14), 
and became the first to be used in clinical practice when it 
was marketed in Japan in December 1995. Recently, a 
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phase II study of seratrodast, in patients with mild to 
moderate asthma, was performed in the United States (15). 
Oral administration of seratrodast inhibited the broncho- 
constriction induced by U-46619 and LTD4 in guinea pig 
(16). BAY ~3405, a selective TXAz antagonist, was also 
reported to attenuate bronchoconstriction induced by U- 
46619 or PGDz in human (17). Seratrodast (40 mg daily for 
4 days) led to a decrease in the dose of methacholine, 
causing a 20% fall in FEVi from 0.43 mg ml-’ to 0.93 mg 
ml-’ in human (18). However its clinical effects have been 
very different in individual subjects. We hypothesized that 
the clinical effects of TXAz receptor antagonist might differ 
according to the production patterns of several arachidonic 
acid metabolites. In this study, we measured urinary ll- 
dehydro-TXBz, 2,3-dinor-6-keto-PGF1, and LTE4, and 
assessed whether these urinary metabolites levels might be 
predictive of the efficacy of seratrodast on asthmatic 
patients. To our knowledge, no reports exist on relationship 
in asthmatic patients between the efficacy of TXAz receptor 
antagonist and urinary arachidonic acid metabolites levels. 
Materials and methods 
SUBJECTS 
All subjects were recruited from Sapporo Medical Uni- 
versity Hospital, Kushiro City General Hospital, Sapporo 
Hospital of Railway Company, Hakodate Municipal 
Hospital and Tomakomai Prefectural Hospital. Fifty 
subjects (28 women and 22 men), aged 23-73 years, were 
chosen at random from a larger group of non-aspirin- 
sensitive asthmatic patients after giving their informed 
consent to participate in this study. Patients were excluded 
from this study if they had a predicted FEVi under 50% or 
over loo%, or if they had ischemic heat diseases, 
hypertension, diabetes mellitus, or nephritis. All patients 
fulfilled the American Thoracic Society (ATS) criteria for 
asthma (19) with a rise in the FEVi of over 15% after S- 
agonist inhalation, and excluded chronic obstructive 
pulmonary disease by pulmonary function tests and 
computed tomographic (CT) scan. All subjects were stable 
and had not suffered from moderate or severe asthma 
exacerbation during the month before this study. Their 
mean resting %FEVi was 82% (range, 5&96%). Forty-five 
subjects were taking inhaled corticosteroid, and two had 
taken oral corticosteroids. Of the 50 asthmatic individuals, 
five were classified as severe asthmatics with predicted 
FEVi values of less than 60%, and requiring a high dose 
(> 800 pg day-‘) of inhaled beclomethasone dipropinate 
(BDP) or oral steroid. Twenty asthmatics had mean 
predicted FEVi values between 60 and 80% and were 
classified as moderate, and the remainder (n = 25) were mild 
asthmatics who had predicted FEVi values greater than 
80%. 
STUDY DESIGN 
At the start of this trial, patients were trained to measure 
peak expiratory flow rate (PEFR) using the Mini-Wright 
Peak Flowmeter (Clement Clark International Ltd., Har- 
low, Essex, U.K.). They took measurements each morning 
(between 0600 and 0800 hours) and evening (between 1800 
and 2000 hours) 2 weeks prior to this trial. The best of three 
performances was recorded as the PEFR. 
On a Daily Record Card, asthma symptoms such as 
asthma exacerbation, wheezing, cough, sputum and dys- 
pnoea were recorded four times a day (morning, afternoon, 
evening and night) from 0 (no symptoms) to 4 (all day), and 
night-time sleep was also recorded from 0 (no disturbance 
of sleep) to 4 (little improvement after inhaler use). This 
symptoms score has been previously reported (20) and we 
modified it. We summed up these daily six asthmatic 
symptoms scores (from 0 to 24) for each 2-week period. 
Adverse events were recorded at each clinic visit. The 
clinical effects were assessed every 2 weeks by PEFR in the 
morning and the asthma symptom scores. The ‘responder’ 
was defined by both of following : 1. Over 15% decrease of 
symptom scores in the last 2 weeks (3-4 weeks after the 
seratrodast treatment) from baseline (2 weeks before the 
therapy) and 2. Over 5% increase of PEFR in the 334 weeks 
from baseline. 
Three-hour urine for l l-dehydro-TXB*, 2,3-dinor-6- 
keto-PGFi,, LTE4 and creatinine was collected between 
09.00 hours and 1200 hours on the first day of this study. 
Subjects received oral seratrodast of 80 mg once a day at 
evening for 4 weeks. Regular medication of each patient 
was not changed during this trial. 
Next, in responders who agreed to continue seratrodast 
treatment for 6 months, we again measured urinary 1 l- 
dehydro-TXBz, 2,3-dinor-6-keto-PGFi, and LTE4 after the 
treatment. 
METHODS 
Urina y crea tinine 
Urine was diluted with water (1 : 30) before measuring 
creatinine. The excretion of urinary eicosanoids was 
calculated in pg mg-’ creatinine. 
Urinary 11-dehydro TXBp and 2,3-dinor-6-keto 
PGFlCt 
Indomethacin was added to the urine sample and stored at 
- 20°C. A volume of 1 ml octadecylsilyl silica (ODS) power 
suspension (80 mg ODS ml-’ 40% ethanol) was added to 
each 1 ml of urine sample under acidic conditions, to 
absorb PGs. Then, ethanol-acid solution (lSO/, ethanol with 
0.05 M HCl) and petroleum ether were added for washing. 
Deproteinization and defatting were performed, and PGs 
were eluted by ethyl acetate. Eluted PGs were applied on a 
Si mini column BOND ELUT Si (Varian, Harbor City, 
CA, U.S.A.) and consequently fractionated by eluent 1 
(chloroform : acetic acid = 100 : 0.5), eluent 2 (acetonitrile : 
chloroform : acetic acid = 10 : 90 : 0.5) and eluent 3 (acetoni- 
trile : chloroform : acetic acid = 25 : 75 : 0.5). The fraction 
obtained by eluent 3 was evaporated by N2 gas and 
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reconstructed by the buffer of the 6-keto-PGFr, [1251] 
Assay System (Amersham International, Little Chalfont, 
U.K.). The volume of 2,3-dinor-6-keto-PGFi, was 
measured with this RIA kit, based on the 31.8% 
cross-reactivity (21). With the same fraction, 1 l-dehydro- 
TXB2 was measured with 1 1-dehydro-thromboxane B2 
[1251] RIA kit (New England Nuclear, Boston, MA, 
U.S.A.). The recovery rates of tritiated 1 I-dehydro-TXBz 
and 2,3-dinor-6-keto-PGF1, were 61.5% and 67.4%, 
respectively. 
Urina y LTE4 
Approximately 30 ml of urine was collected in 
polypropylene containers from each patient. An internal 
standard of 3H-LTE4 (20 000 dpm, 33pg LTE4, DuPont 
New England Nuclear Research, Boston, MA, U.S.A.) 
was added to the remaining sample. Immediately after 
collection, 4 ml of solution 1 (ethyl acetate:metha- 
nol=2 : 1) was added to each 1 ml of urine specimen to 
eliminate proteins; the specimens were then frozen at 
-70°C until the assays for urinary creatine and LTE* 
could be performed. All samples were analysed within 1 
month of collection. The method that was used to analyse 
urinary LTE4 levels was modified from Tagari et al. (22). 
Briefly, 5 ml of each urine sample was centrifuged at 
2000 g for 15 min to remove any particulates. The 
supernatant was washed with 3 ml of petroleum ether 
and centrifuged at 2000 g for 15 min. A volume of 5 ml of 
0.05 M acetic acid buffer (pH4.0) was added to the lower 
layer to eliminate lipid and loaded into a C8 mini column 
(Bond Elut C8, Varian, Harbar City, CA, U.S.A.) and 
washed consecutively with 4 ml of hexane, 8 ml of solution 
2 (hexane : ethyl acetate=95 : 5), 4 ml of solution 3 
(hexane:ethyl acetate= 30: 70) and 4 ml of solution 4 
(acetone : methanol = 50 : 50). The fraction obtained by 
solution 4 was evaporated by N2 gas and reconstructed 
by 200 1 of solution 5 (methanol: water: acetic 
acid= 65 : 35 : 1, pH 5.6 with triethylamine). A reverse 
phase-high pressure liquid chromatography (RP-HPLC) 
gradient system equipped with a Nova-Pak Cl8 column 
(Waters Assoc., Milford, MA, U.S.A.) was used to separate 
the individual pepetidoleukotrienes from each other 
and from other potential non-leukotriene cross reacting 
substances. The sample (150 ~1) was injected into the 
column at a flow rate of 1 ml/min and LTE4 was eluted at 
11-13.5 min with this system. Each fraction was 
evaporated, and the residue was redissolved in 125 ~1 of 
the buffer of a commercial radioimmunoassay (RIA) 
kit; peptidyl leukotriene [3H] RIA kit (DuPont New 
England Nuclear Research, Boston, MA, U.S.A.). LTE4 
was also measured using the same kit assay buffer. The RIA 
was carried out according to the method by Hayes et al. 
(23) with some modifications. The measurements were 
corrected by the creatinine content of urine; levels were 
expressed as pg mg- ’ creatinine. The recovery rate of 
tritiated LTE4 was 50-65%. The intra-assay and interassay 
coefficients of variation were 11% and lo%, respectively. 
DATA ANALYSIS 
The data of patients’ backgrounds (in Table 1) and urinary 
eicosanoids are described as mean + SE, and the differences 
between the groups were tested with the Mann-Whitney U- 
test. The chi-square test was used to test the association of 
categorical variables. Comparisons of PEFR and Asthma 
Symptoms Score at baseline and every 2-week interval were 
made by analysis of variance (ANOVA) and Scheffe’s test, 
and described as mean & SE. The Wilcoxon test was used in 
the comparisons of urinary level eicosanoids and their 
ratios between before and after 6 months seratrodast 
treatment. Peason’s least squares linear regression analysis 
was used to determine correlations. Differences with a P 
value of less than 0.05 were considered statistically significant. 
Results 
Of the 50 patients entering this study, four were excluded 
because of an incomplete examination and one was 
eliminated because of nausea caused by the adverse effect 
of seratrodast, which disappeared one day after the 
cessation of administration. In the remaining 45 patients, 
18 were defined as responders and 27 as non-responders. 
The Asthma Symptoms Score at week 34 were signifi- 
cantly (P < 0.00 1) reduced in responders (- 25.1%) from 
baseline), but not in non-responder (-2.6%, from base- 
line). Mean PEFR of all 45 patients at week 3-4 increased 
in both the morning (5.8% f 1.8) and evening (4.8% f 1.3). 
PEFRs of responders in weeks 34 were significantly 
increased (P<O.Ol) compared with those of the baseline 
period; morning (10.7% + 1.6) and evening (9.2% + 1.9) 
(Fig. 1). The mean increased PEFR values in morning and 
evening were 40 1 min-’ and 34 1 min-‘, respectively. 
The characteristics and baseline urinary eicosanoid levels 
of the 45 patients are shown in Table 1. There were no 
significant differences between the two groups in patients’ 
characteristics, asthma severity, baseline lung functions, 
treatments and each urinary eicosanoid. However, the ratio 
of 11-dehydro-TXBz to LTE4 of responders was signifi- 
cantly higher (7.49+0.71 vs. 5.09f0.67; P= 0.0091) than 
that of non-responders (Fig. 2). Urinary LTE4 levels and 
the LTE4/2,3-dinor-6-keto-PGFI, ratio were lower in 
responders, but not significantly. 
In all 45 patients there was a trend of correlation between 
urinary 1 I-dehydro-TXBz/LTEd ratio and the decrease of 
Asthma Symptoms Score at weeks 3-4 (r = 0.40, P= 0.07), 
however there was no significant relationship between the 
other urinary eicosanoids ratios and Asthma Symptoms 
Score. 
In the 11 patients with 6 months treatment of seratro- 
dast, Asthma Symptoms Scores at week 23-24 were 
significantly (P-c 0.05) reduced in the responders 
(-20.3%, from baseline), and PEFRs in weeks 23-24 were 
significantly (PcO.05) increased from the baseline, both in 
the morning (9.9% + 2.0) and evening (8.2% f 1.9). Only 
the 1 I-dehydro-TXBz/LTEd ratio had a tendency to 
decrease during the 6 months treatment as shown in Table 2. 
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TABLE 1. Characteristics of patients and response to seratrodast 
Responder Non-responder 
n=18 n=27 
P value 
Sex; women/men 
Age; yr (range) 
Atopy; yes/no 
Duration of asthma; yr (range) 
Smoking; yes/no 
Baseline FEVl, L 
Predicted FEVI, % 
Asthma symptoms score 
Oral steroid, Yes/no 
Inhaled BDP, yes/no 
Dose of BDP, mg day- ’ (range) 
Theophyllin, yes/no 
Severity of asthma, severe & moderate/mild 
Baseline urinary aracidonate 
1 1-dehydro-TXBz, mg- ’ creatinine pg 
LTE4, pg mg- ’ creatinine 
2,3-dinor-6-keto-PGFlq pg mg-’ creatinine 
11 -dehydro-TXBz/LTEJ ratio 
11-dehydro-TXBJ2,3-dinor-6-keto-PGFlm 
LTE4/2,3-dinor-6-keto-PGF1a ratio 
s/10 16/11 0.33 
58 + 2 (23-69) 58 + 2 (36-69) 0.80 
1216 10/17 0.051 
11&3 (340) 12 f 2 (2-36) 0.57 
4114 5122 0.76 
2.30f0.18 1.96kO.16 0.13 
87.8k6.2 79.5k5.6 0.23 
19.5 f0.9 21.3kO.8 0.12 
l/17 l/26 0.77 
17/l 2512 0.81 
694k75 (400-1200) 600 + 60 (400-1200) 0.29 
1216 19/8 0.79 
8/10 15/12 0.46 
905 * 73 826 f 73 0.40 
136+ 15 223+31 0.068 
364 jy 36 312+38 0.14 
7.49kO.71 5.09 f 0.67 0.0091 
4.3k1.5 3.6kO.37 0.22 
0.54kO.17 1.39f0.45 0.057 
BDP:beclomethasone dipropionate. Mean f SE. 
20 - 
-4 - 
- 2 to -1 week 
(Baseline) 
l-2 week 3-4 week 
FIG. 1. Effect of 4-week treatment with seratrodast on 
morning peak expiratory flow rate in responders and non- 
responders. Asterisk indicates P < 0.0 1 compared with the 
baseline period. 0-O: responder; 0-a: non-responder; 
PEFR: peak expiratory flow rate. 
Discussion 
This is the first clinical trial demonstrating the relationship 
between the efficacy of TXAz receptor antagonist and 
baseline urinary eicosanoids levels in asthmatic patients. 
We found that seratrodast was more effective in patients 
16 1 
Responder 
(n = 18) 
Non-responder 
(n = 27) 
FIG. 2. Baseline ratio of urinary 1 1-dehydro-TXBz/LTEd 
in responders and non-responders. The rectangle gives 
the range from the 25 to the 75% percentile, the 
horizontal line indicates the median, and the vertical line 
indicates the range from the 10 to the 90% percentiles. 
P=O.O091. 
with a high ratio of urinary ll-dehydro-TXBz/LTEd, and 
that this ratio had a weak correlation with changes in the 
Asthma Symptom Score. These results suggested that 
responders to seratrodast might have an imbalance of TX 
and LT production in terms of relative ratio, but not in 
absolute levels. However, Urinary LTE4 level was lower, 
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TABLE 2. Changes in urinary arachidonic acid metabolites before and after 6 months treatment with seratrodast in asthmatic 
patients (n = 11) 
Before treatment After 6 months P value 
1 1-dehydro-TXBz (pg mgg ’ creatinine) 
LTE4 (pg mg-’ creatinine) 
2,3-dinor-6-keto-PGFia (pg mg-’ creatinine) 
11 -dehydro-TXBz/LTE4 ratio 
1 I-dehydro-TXBz/2,3-dinor-6-keto-PGFiti ratio 
LTE4/2,3-dinor-6-keto-PGFia ratio 
862f 106 751 f93 0.33 
156k30 169&32 0.53 
283 f 50 247 + 39 0.86 
6,7+ 1.3 4.5f0.7 0.083 
4.4f 1.0 3.5kO.5 0.48 
1.2f0.5 1.8f0.7 0.53 
Mean + SE. 
but not significantly so, in responders and the fact that the 
LTE4/ 2,3-dinor-6-keto-PGF1, ratio was also lower may be 
a result of the low LTE4 level. We could not explain the 
interindividual difference of each eicosanoid production. 
One possible reason could be the difference in the number 
and sensitivity of each eicosanoid receptor. The ll- 
dehydro-TXBz/LTE4 ratio had a tendency to decrease after 
6 months treatment with seratrodast. As seratrodast had no 
inhibitory effect on TXAz synthesis, this decrease might 
occur following an improvement of asthma by seratrodast. 
Theophylline infusion had hardly any effect on in vivo 
TXA2, PGIz or LTs production measured as urinary 
metabolites (24), and systemic steriods had little effect on 
arachidonic acid metabolites (25). However therapeutic 
regimens of glucocorticoids suppressed the release of TXB2 
and LTs (26,27). Since no significant differences existed 
between responders and non-responders in the doses of 
inhaled corticosteroid and theopylline, baseline treatments 
in this study would not affect the results of urinary 
arachidonic acid metabolites. 
There were no significant differences in asthma severity 
between responders and non-responders in this study. 
TXAz was originally described as being released from 
platelets (28), but is now known to be released from other 
cells, including macrophages and neutrophils in the airway 
(29). Wenzel et al. (11) reported that the ongoing release of 
TXA2 and LTs into bronchoalveolar lavage fluid was found 
in some severe asthmatic patients undergoing high dose 
glucocorticoid therapy. On the other hand, our preliminary 
data (not shown) revealed that degrees of absolute levels of 
urinary 11-dehydro-TXB2 or LTE4 did not correlate with 
asthma severity. In this study, we speculated that asthmatic 
patients who had a tendency to generate more TXAz than 
LTs might have a TXAz dominant asthmatic reaction 
pathway, and therefore TXAz antagonist might be more 
effective. To test this hypothesis, a further study assessing 
the effects of seratrodast in asthmatic patients with a high 
ratio of 1 1-dehydro-TXBx/LTE4 is needed. 
The limitation of this study was that it was not a double- 
blind placebo study. The 40% response rate to seratrodast 
in this study might not be generalized. However, the aim of 
this study was not to evaluate the efficacy of seratrodast but 
to look for the difference between responders and non- 
responders to seratrodast. Our data suggested that no 
significant differences in clinical characteristics existed 
between the two groups. If systemic TXAz/LTs ratio is a 
predictor of the effects of TXA;! receptor antagonist, 
urinary measurement may be favourable because the 
procedure is non-invasive and urinary arachidonic acid 
metabolites are more stable than those in blood. 
Seratrodast has an antagonism to TXAz/PGHz receptor 
(TP receptor) on bronchial smooth muscle cells and 
platelets (30). PGDz, as well as TXAz, contributes to 
bronchoconstriction through the TP receptor on smooth 
muscle cells (31) and therefore the clinical effects of 
seratrodast might also be dependent on this mediator. This 
could be one of the reasons why the ratio of urinary ll- 
dehydro-TXBz/LTE* did not significantly correlate with 
changes in asthma symptoms in this study. The relationship 
between the efficacy of seratrodast and urinary PGDz 
metabolites, such as 9a, 11 B-PGF2a, should also be further 
examined. 
We measured 3 h urine collected between 090&1200 
hours. Urinary levels of LTE4 and 11-dehydro-TXBz 
increase after asthma exacerbation (5,6), so to exclude this 
influence we selected patients without asthma exacerbation 
within the 1 month period before this trial. Urinary 1 l- 
dehydro-TXBz level had a circadian rhythm with acrophase 
in early morning, but the circadian rhythmicity of urinary 
LTE4 was inconsistent (32-34). We recently measured every 
3 h urine in different asthmatic patients over a 24 h period 
and both urinary 11-dehydro-TXBz and LTE4 had circa- 
dian rhythmicity (35), and the mean of every 3 h value was 
close to that collected between 0900-1200 hours. It seems 
important to consider circadian rhythmicity in an evalua- 
tion of urinary eicosanoids. 
In our study, tachyphylaxis did not occur during 
seratrodast treatment, and urinary levels of 1 l-dehydro- 
TXBz did not increase for 6 months. This result suggested 
that there was no feedback mechanism in systemic TXA2 
generation by long-term treatment with oral TXAz receptor 
antagonist. Other eicosanoids also did not change, there- 
fore TXAz antagonist might not affect individual baseline 
arachidonic acid metabolites production patterns. Urinary 
1 1-dehydro-TXBz excretion has been shown to increase 
during severe asthmatic exacerbations (36). It is well known 
that urinary eicosanoids levels may vary due to physiolo- 
gical events. However, the measurements of arachidonates 
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using spot urine samples seemed to be a reliable method if 
acute exacerbation had not occured within one month prior 
to this. 
In conclusion, we assessed the clinical efficacy of 4 weeks 
treatment with seratrodast and 18 out of 45 asthmatic 
patients were responders. The ratio of 11-dehydro-TXBz/ 
LTE4 of responders was significantly higher than that of 
non-responders. In all 45 subjects there was a weak, but not 
significant, correlation between urinary 1 1-dehydro-TXBz/ 
LTE4 ratio and changes in the Asthma Symptom Score. 
There was no tachyphylaxis during the 6 months treatment, 
and this urinary ratio had a tendency to decrease during 
this period. These results suggested that the clinical 
response to seratrodast in asthmatic patients might be 
predictable from the ratio of urinary eicosanoids. 
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